MyFinsight
Home
About
Contact
bbio: the income statement
Download
Download image
Net loss
attributable to common...
-$182,743K
(-12.78%↓ Y/Y)
Net loss
attributable to redeemable...
-$2,194K
(0.90%↑ Y/Y)
Net loss
-$184,937K
(-12.59%↓ Y/Y)
Provision for (benefit
from) income taxes
-$1,545K
Loss before income
taxes
-$186,482K
Royalty
$4,278K
License And Service
$8,311K
Product
$108,111K
Total other income
(expense), net
-$41,283K
(-250.14%↓ Y/Y)
Loss from operations
-$145,199K
(24.28%↑ Y/Y)
Other income, net
$16,461K
(816.03%↑ Y/Y)
Total revenues, net
$120,700K
(4318.01%↑ Y/Y)
Interest income
$6,239K
(89.29%↑ Y/Y)
Net loss from equity
method investments
-$15,834K
(-141.26%↓ Y/Y)
Noncash interest
expense on deferred...
$36,410K
Total operating costs
and expenses
$265,899K
(36.72%↑ Y/Y)
Interest expense
$11,739K
(-49.10%↓ Y/Y)
Restructuring, impairment and
related charges
$8,841K
Selling, general and
administrative
$137,621K
(99.98%↑ Y/Y)
Research and development
$112,874K
(-6.29%↓ Y/Y)
Total cost of revenues
$6,563K
(997.49%↑ Y/Y)
License Services And
Royalty
$2,535K
Product
$4,028K
Back
Back
Income Statement
source: myfinsight.com
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)